B01 Mutagenic and tumorigenic effects of follicular fluid in the context of p53 loss: Initiation of fimbria carcinogenesis. Tang-Yuan Chu, Department of Obstetrics & Gynecology, Buddhist Tzu Chi General Hospital, Hualien, Taiwan.

B02 Oxidized hemoglobin promotes survival of ROS-stressed and DNA damaged fallopian tube epithelial cells with p53 loss, resulting in a copy number variation phenotype of HGSC. Hsuan-Shun Huang, Cervical Cancer Prevention Center, Department of Medical Research, Buddhist Tzu Chi General Hospital, Hualien, Taiwan.

B03, PR12 Mutant p53 drives early events in fallopian tube tumorigenesis through mesenchyme-associated autocrine production of matrix that supports survival and mesothelial intercalation. Marcin Iwanicki, Harvard Medical School, Boston, MA, United States.

B04 Early detection of ovarian cancer recurrence using p53-mutated circulating tumor DNA as non-invasive biomarkers. Ha-Young Lee, University of Ulsan College of Medicine, Seoul, Korea, Republic Of.

B05 Assessment of TP53 mutation status in primary high-grade serous ovarian cancer and cell line models: Comparison between immunohistochemistry and next generation sequencing. Deborah Marsh, Hormones and Cancer Group, Kolling Institute of Medical Research, University of Sydney, Sydney, NSW, Australia.

B06, PR13 A designed inhibitor of p53 self-aggregation rescues p53 tumor-suppression function in high-grade serous ovarian carcinoma. Alice Soragni, University of California, Los Angeles, Los Angeles, CA, United States.


B08 Genomics analyses of less common epithelial ovarian cancer subtypes. Ian Campbell, Peter MacCallum Cancer Centre, Melbourne, Vic, Australia.

B09 Roles of iASPP, PLK1 and autophagy in ovarian clear cell carcinoma. Ka Kui Chan, University of Hong Kong, Hong Kong, China.

B10 FOXL2 402C>G mutation can be identified in the circulating tumour DNA of patients with adult-type granulosa cell tumor. Anniina Färkkilä, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland.

B11 Mutational heterogeneity in non-serous ovarian cancers. Anxhela Gjyshi, University of South Florida Cancer Biology PhD Program, Tampa, FL, United States.

B13 Discovery of novel subtype-specific ovarian cancer biomarkers via integrated tissue proteomics. Felix Leung, Mount Sinai Hospital, Toronto, ON, Canada.

B14 Molecular characterization of mucinous ovarian carcinoma. Brooke Schlappe, Memorial Sloan Kettering Cancer Center, New York, NY, United States.

B15 Concomitant loss of SMARCA2 and SMARCA4 expression in small cell carcinoma of the ovary, hypercalcemic type. Jill Tseng, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States.

B16 Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated ovarian cancers. Rugang Zhang, The Wistar Institute, Philadelphia, PA, United States.

B17 Type 2 diabetes, metformin, and ovarian cancer survival: An analysis of tumor registry and electronic medical record data. Alicia Beeghly-Fadiel, Vanderbilt University Medical Center, Nashville, TN, United States.

B18 Pre-diagnostic physical inactivity and epithelial ovarian cancer risk and mortality: Evidence from the Ovarian Cancer Association Consortium. Rikki Cannito, Roswell Park Cancer Institute, Buffalo, NY, United States.

B19, PR16 Computational modeling of serous ovarian carcinoma dynamics: Implications for screening and therapy. Shengqing Gu, University of Toronto, Princess Margaret Cancer Center, Toronto, ON, Canada.


B21 BRCA mutation status is not associated with better long-term survival from epithelial ovarian cancer. Joanne Kotsopoulos, Women's College Research Institute, Toronto, ON, Canada.

B22 Exploring the effects of incomplete pregnancies on risk of ovarian cancer. Alice Lee, University of Southern California, Keck School of Medicine, Los Angeles, CA, United States.

B23, PR10 Detection of Müllerian duct carcinomas by lavage of the uterine cavity and mutation analysis: A new concept. Elisabeth Maritschnegg, Medical University of Vienna, Vienna, Austria.

B24 Personal history of endometriosis and survival in ovarian cancer patients: A pooled analysis of 10 studies from the Ovarian Cancer Association Consortium. Albina Minlikeeva, University at Buffalo, Buffalo, NY, United States.

B25 Preclinical evaluation of radiolabeled MUC16 antibodies for PET imaging of epithelial ovarian carcinoma. Brandon Nemieboka, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
**Poster Session B**  
**Monday, October 19, 2015**  
12:45 p.m. – 3:30 p.m.  
Plaza International Ballroom D-F

**B26** Cell surface expression of CD44v8-10 is associated with good prognosis while cleaved extracellular domain is a marker of poor prognosis in high-grade serous epithelial ovarian cancer. David Pepin, Massachusetts General Hospital, Boston, MA, United States.

**B27** Investigation of small GTPase genes in epithelial ovarian cancer. Catherine Phelan, Moffitt Cancer Center, Tampa, FL, United States.

**B28** Validation of a combined 13 gene six protein blood signature for earlier detection of ovarian cancer. Dietmar Pils, Comprehensive Cancer Center & Medical University of Vienna, Vienna, Austria.

**B29** Pre- and post-diagnosis analgesic use and ovarian cancer survival. Elizabeth Poole, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, United States.

**B30** Dietary Fat Intake and Ovarian Cancer Risk. Megan Rice, Brigham and Women's Hospital, Boston, MA, United States.

**B31** Circulating periostin as a potential biomarker to predict platinum-resistant epithelial ovarian cancer. Lisa Ryner, Genentech, Inc, South San Francisco, CA, United States.

**B32** Serum Calcium and Serum Albumin Can Discriminate Malignant from Benign Pelvic Masses. Gary Schwartz, University of North Dakota, Grand Forks, ND, United States.

**B33** Reproductive and hormonal risk factors in relation to ovarian cancer survival and platinum resistance. Amy Shafrir, Harvard T.H. Chan School of Public Health, Boston, MA, United States.


**B35** Ovarian cancer incidence projections in the United States: expected increases through 2030. Sherri Stewart, Centers for Disease Control and Prevention, Atlanta, GA, United States.

**B36** In vivo laser-based imaging of the human fallopian tube for future cancer detection. Elizabeth Swisher, University of Washington, Seattle, WA, United States.

**B37** Menstrual cycle characteristics, PCOS, and ovarian cancer risk. Kathryn Terry, Brigham & Women's Hospital, Boston, MA, United States.

**B38**, **PR11** Pre-diagnosis adiposity, physical activity and ovarian cancer survival. Adetunji Toriola, Washington University School of Medicine, St. Louis, MO, United States.

**B39** Serum estrogen and estrogen metabolites and risk of ovarian cancer among postmenopausal women in the Women's Health Initiative Observational Study. Britton Trabert, National Cancer Institute, Bethesda, MD, United States.

**B40** Pre-diagnosis leukocyte telomere length and risk of ovarian cancer. Shelley Tworoger, Brigham and Women's Hospital & Harvard Medical School, Boston, MA, United States.
B41 Methylation profiling of ovarian cancer to study etiologic and prognostic heterogeneity and to develop a molecular classifier. Nicolas Wentzensen, National Cancer Institute, Bethesda, MD, United States.

B42 Identification of nucleic acid aptamers for ovarian cancer biomarkers using multiple selection modes and high-throughput sequencing. Rebecca Whelan, Oberlin College, Oberlin, OH, United States.

B43 Characterization of ovarian cancer cells as in vivo models for preclinical studies. Christina Annunziata, National Cancer Institute, Bethesda, MD, United States.

B44, PR08 Evidence for extra-ovarian origin and peritoneal metastases that precede ovarian carcinomas in high-grade serous ovarian cancer. Jeremy Chien, University of Kansas Medical Center, Kansas City, KS, United States.

B45 Characterization of human fallopian tube epithelial stem-like cells. Dah-Ching Ding, Department of Obstetrics and Gynecology, Buddhist Tzu Chi General Hospital, Tzu Chi University, Hualien, Taiwan, Taiwan.

B46 Use of a novel orthotopic ovarian cancer transplant patient derived xenograft model as a preclinical platform for bench to bedside research. Erin George, University of Pennsylvania, Philadelphia, PA, United States.

B47 Novel integrative approach to identify therapy sensitive and insensitive ovarian cancer patients. Sampsa Hautaniemi, University of Helsinki, Helsinki, Finland.

B48 Design of effective combination therapies for high-grade serous ovarian cancer using patient-derived xenograft models. Claudia Iavarone, Department of Cell Biology, Ludwig Center at Harvard, Harvard Medical School, Boston, MA, United States.

B49 Giant cancer stem cells of high-grade ovarian serous carcinoma. Jinsong Liu, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

B50 Anti-neoplastic activity of Top I inhibitor etirinotecan pegol (NKTR-102) and PARP inhibitor rucaparib (CO-388) in platinum-resistant high-grade serous BRCA WT ovarian cancer PDX models. Caroline Nitschmann, Mayo Clinic, Rochester, MN, United States.


B52 The epithelial-mesenchymal transition factor Snail represses the tumor suppressor microRNA let-7 and contributes to invasiveness of ovarian cancer cells. Juli Unternaehrer-Hamm, Loma Linda University, Loma Linda, CA, United States.
B53 CRISPR/Cas9 mediated p53 and BRCA2 knockout to generate improved murine models of high-grade serous ovarian cancer. Josephine Walton, Barts Cancer Institute/The University of Glasgow, London/Glasgow, United Kingdom.

B54 Single and collective cell dissemination modes in ovarian cancer. Sara Al-Habayan, Rosalind and Morris Goodman Cancer Research Centre, Montreal, QC, Canada.

B55 Peritoneal tumor spread in high-grade serous ovarian cancer: Differences in the immune response. Katharina Auer, Comprehensive Cancer Center & Medical University of Vienna, Vienna, Austria.

B56 Peritoneal tumor spread in high-grade serous ovarian cancer: An effect of the competing endogenous RNA network?. Anna Bachmayr-Heyda, Comprehensive Cancer Center & Medical University of Vienna, Vienna, Austria.

B57 Sucrose nonfermenting 1-related kinase (SNRK) expression and function in ovarian cancer. Erin Bishop, Medical College of Wisconsin, Milwaukee, WI, United States.

B58 Functional analysis of the cell adhesion molecule Nectin-4 in the unique tumor microenvironment of ovarian cancer. Kristin Boylan, University of Minnesota, Minneapolis, MN, United States.

B59 The adhesion molecule L1: a new driver in ovarian cancer vasculature. Ugo Cavallaro, European Institute of Oncology, Milano, Italy.

B60 Identification of an ovarian tumor:stromal HH:BMP4 signaling loop critical to ovarian cancer growth and chemotherapy resistance. Lan Coffman, University of Michigan Medical Center, Ann Arbor, MI, United States.

B61 Leptin induces a pro-inflammatory macrophage-cancer cell reinforcement loop that favors high-grade serous ovarian cancer progression among overweight/obese women. Mauricio Cuello, Division Obstetrics and Gynecology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Area Metropolitana, Chile.

B62 Discoidin domain receptor 2 (DDR2) modulates invasion and metastasis via epithelial mesenchymal transition in ovarian cancer. Katherine Fuh, Washington University, St. Louis, MO, United States.

B63 Expression of VEGF in ovarian cancer suppresses tumor immunity through recruitment of myeloid-derived suppressor cells. Naoki Horikawa, Kyoto University, Kyoto, Japan.

B64 Suboptimal cytoreduction in ovarian carcinoma is associated with molecular pathways characteristic of increased stromal activation. Dongyu Jia, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
B65, PR17 Characterization of ascites and tumor derived ovarian cancer stem-like cells. Katja Kaipio, Department of Pathology, University of Turku and Turku University Central Hospital, Turku, Finland.

B66 Blockade of PD-1 signaling in tumor-associated dendritic cells results in compensatory IL-10 release maintaining immune suppression in ovarian cancer microenvironments. Keith Knutson, Mayo Clinic, Jacksonville, FL, United States.

B67 The impact of parity on the metastatic success of ovarian cancer. Elizabeth Loughran, University of Notre Dame, Notre Dame, IN, United States.

B68 Erythropoietin Stimulates Ovarian Tumor Growth via EphB4. Sunila Pradeep, University of Texas MD Anderson Cancer Center, Houston, TX, United States.

B69 Notch3 signal activation promotes peritoneal metastasis in a mouse model of epithelial ovarian cancer. Jessica Price, Columbia University Medical Center, New York, NY, United States.

B70 Targeted activation of macrophages to limit ovarian cancer progression. Fiona Yull, Vanderbilt University, Nashville, TN, United States.

B71 Old age and chemotherapy contribute to the selection of PPM1D somatic mosaic mutations in ovarian cancer. Maria Harrell, University of Washington, Seattle, WA, United States.

B72 Long term survival and outcome update on patients (pts) with recurrent ovarian cancer who received Ipilimumab post GVAX vaccine. Ursula Matulonis, Dana-Farber Cancer Institute, Boston, MA, United States.

B73 The monoterpene, citral, increases intracellular oxygen radicals and inhibits cancer cell proliferation by inducing apoptosis and endoplasmic reticulum stress. Manish Patankar, University of Wisconsin-Madison, Madison, WI, United States.

B74 Can we repurpose anti-malarial drug quinacrine to treat ovarian cancer?. Viji Shridhar, Mayo Clinic, Rochester, MN, United States.

B75 Increased basal autophagy decreases sensitivity to cisplatin in chemoresistant ovarian cancer. Thomas Silvers, Icahn School of Medicine at Mount Sinai, New York, NY, United States.

B76 INVOLUNTARY WEIGHT LOSS IS AN INDEPENDENT PROGNOSTIC FACTOR FOR OVERALL SURVIVAL AND PREDICTS BETTER RESPONSE TO CHEMOTHERAPY IN HIGH GRADE SEROUS OVARIAN CANCER PATIENTS. J. Sznurkowski, Medical University of Gdansk, Gdansk, Poland.

B77 Examining selection for resistant clones in high-grade serous ovarian cancer after neoadjuvant chemotherapy. Alicia Tone, Princess Margaret Cancer Centre, Toronto, ON, Canada.

B78 Differential methylation of HIST1H2BB and MAGI2 in ovarian cancers. Blanca Valle, Johns Hopkins University-School of Medicine, Baltimore, MD, United States.
Poster Session B  
Monday, October 19, 2015  
12:45 p.m.–3:30 p.m.  
Plaza International Ballroom D–F

B79 Translational study of tumor treating fields in combination with paclitaxel in ovarian cancer. Tali Voloshin, Novocure Ltd, Haifa, Israel.

B80 Tumor expression subtypes of high-grade serous ovarian cancer demonstrate associations with likelihood of complete resection: a single-center study. Chen Wang, Mayo Clinic, Rochester, MN, United States.

B81 The histone deacetylase inhibitor panobinostat sensitizes cyclin E-amplified ovarian cancer cells to the cyclin-dependent kinase 2 inhibitor dinaciclib. Andrew Wilson, Vanderbilt University Medical Center, Nashville, TN, United States.

B82 Application of modulated electro-hyperthermia for the cellular target therapy in ovarian cancer cells. Wookyeom Yang, Yonsei University, Seoul, Korea, Republic Of.